Researchers at the University of Michigan have developed SH-273, a dual-target drug that both activates immune pathways and blocks resistance mechanisms in pancreatic cancer. In mouse models, it ...
A University of Michigan team has created SH-273, a dual-target drug that activates STING while inhibiting PI3Kγ to counter immune suppression in pancreatic cancer. In mouse models, it extended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results